(RMD) ResMed - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078
RMD: Medical Devices, Software Applications
ResMed Inc. (NYSE: RMD) is a global leader in developing, manufacturing, and distributing medical devices and cloud-based software solutions for the healthcare industry. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its product portfolio includes advanced diagnostic tools such as ApneaLink Air, a portable device that measures multiple physiological parameters for sleep apnea diagnosis, and NightOwl, a cloud-connected, disposable diagnostic device that assesses AHI using peripheral arterial tone, actigraphy, and oximetry over several nights. ResMed also offers a suite of software solutions like AirView, which enables remote patient monitoring and device setting adjustments, and myAir, a patient engagement app designed to improve therapy adherence for sleep apnea patients. Additionally, the company provides U-Sleep, a compliance monitoring solution for home medical equipment providers, and Propeller, a connectivity module and portal for enhanced disease management.
ResMeds out-of-hospital software solutions include Brightree, a comprehensive business management platform for home medical equipment, pharmacy, and home infusion providers; MatrixCare, which offers care management solutions for senior living and skilled nursing facilities; HEALTHCAREfirst, providing electronic health records, billing, and analytics for home health and hospice agencies; and MEDIFOX DANs software solutions. The company distributes its products through a network of distributors and direct salesforce, targeting sleep clinics, home healthcare dealers, and hospitals. Founded in 1989 and headquartered in San Diego, California, ResMed has established itself as a key player in the healthcare technology sector. Web URL: https://www.resmed.com
Additional Sources for RMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RMD Stock Overview
| Market Cap in USD | 34,363m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 1995-06-02 |
RMD Stock Ratings
| Growth Rating | 28.5 |
| Fundamental | 93.0 |
| Dividend Rating | 55.5 |
| Rel. Strength | 9.6 |
| Analysts | 3.72/5 |
| Fair Price Momentum | 219.86 USD |
| Fair Price DCF | 206.18 USD |
RMD Dividends
| Dividend Yield 12m | 0.88% |
| Yield on Cost 5y | 1.36% |
| Annual Growth 5y | 5.30% |
| Payout Consistency | 100.0% |
RMD Growth Ratios
| Growth Correlation 3m | -70.4% |
| Growth Correlation 12m | 37.3% |
| Growth Correlation 5y | 17.9% |
| CAGR 5y | 9.29% |
| CAGR/Max DD 5y | 0.17 |
| Sharpe Ratio 12m | 0.44 |
| Alpha | 1.63 |
| Beta | 0.788 |
| Volatility | 59.70% |
| Current Volume | 718.1k |
| Average Volume 20d | 1439k |
As of April 30, 2025, the stock is trading at USD 237.74 with a total of 718,085 shares traded.
Over the past week, the price has changed by +11.05%, over one month by +6.21%, over three months by -5.77% and over the past year by +10.45%.
Yes, based on ValueRay Fundamental Analyses, ResMed (NYSE:RMD) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.96 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RMD as of April 2025 is 219.86. This means that RMD is currently overvalued and has a potential downside of -7.52%.
ResMed has received a consensus analysts rating of 3.72. Therefor, it is recommend to hold RMD.
- Strong Buy: 6
- Buy: 3
- Hold: 8
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, RMD ResMed will be worth about 244.9 in April 2026. The stock is currently trading at 237.74. This means that the stock has a potential upside of +3.02%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 263.2 | 10.7% |
| Analysts Target Price | 256 | 7.7% |
| ValueRay Target Price | 244.9 | 3% |